Home › Triple-Negative Breast Cancer › Pennsylvania › Philadelphia
Triple-Negative Breast Cancer clinical trials in Philadelphia, PA
13 studies for Triple-Negative Breast Cancer are looking for participants at sites in and around Philadelphia (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RecruitingPhase 1
- Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia
Study of AVZO-021 in Patients With Advanced Solid Tumors
RecruitingPhase 1/2
- Avenzo Therapeutics Recruiting Site, Philadelphia
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
RecruitingPhase 3
- Sidney Kimmel Cancer Center at Jefferson ( Site 0049), Philadelphia
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
RecruitingPhase 2
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RecruitingPhase 3
- University of Pennsylvania Abramson Cancer Center, Philadelphia
- Lankenau Medical Center, Wynnewood · 7 mi away
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RecruitingPhase 1
- Normunity Investigational Site, Philadelphia
- Normunity Investigational Site, Philadelphia
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
RecruitingPhase 2/3
- Abramson Cancer Center of The University of Pennsylvania, Philadelphia
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RecruitingPhase 2
- University of Pennsylvania (U Penn), Philadelphia
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
RecruitingPhase 2
- University of Pennsylvania-Abramson Cancer Center, Philadelphia
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RecruitingPhase 2
- University of Pennsylvania-Abramson Cancer Center, Philadelphia
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
Recruiting
- Thomas Jefferson University Hospital, Philadelphia
Role of the Immune Environment in Response to Therapy in Breast Cancer
RecruitingObservational study
- Abramson Cancer Center, Philadelphia
Triple-Negative Breast Cancer trials in other cities
- Houston, TX42 studies
- New York City, NY31 studies
- Nashville, TN28 studies
- Los Angeles, CA27 studies
- Boston, MA26 studies
- San Antonio, TX23 studies
- St. Louis, MO21 studies
- Arlington, VA20 studies
- Atlanta, GA20 studies
- Dallas, TX18 studies
- Chicago, IL16 studies
- Columbus, OH16 studies
Other studies in Philadelphia
- Cancer (all types)59 studies
- Breast Cancer56 studies
- Non-Small Cell Lung Cancer51 studies
- Metastatic Cancer46 studies
- Prostate Cancer44 studies
- Colorectal Cancer44 studies
- Ovarian Cancer44 studies
- Lung Cancer36 studies
- Acute Myeloid Leukemia34 studies
- Heart Failure31 studies
- Endometrial Cancer28 studies
- Depression26 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.